Precedent for this type of treatment exists, in theory, as in utero administration of BMP2/7 rescues the skeletal defects associated with a mouse model of Rubinstein-Taybi syndrome [66]. This evidence concerns the gene BMP2 and Rubinstein-Taybi syndrome.